Brief: Effector Therapeutics To Present Interim Data From Ongoing Zotatifin Phase 1/2 Dose Escalation And Expansion Trial
May 26 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS TO PRESENT INTERIM DATA FROM ONGOING
ZOTATIFIN PHASE 1/2 DOSE ESCALATION AND EXPANSION TRIAL AT 2022
ASCO ANNUAL MEETING
Source text for Eikon: ID:nGNX7fy6JL
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright